Lysando AG and Amicogen Inc. Sign General Development Agreement
businesswire.com
news
2022-10-18 00:00:00

October 18, 2022 04:13 AM Eastern Daylight Time TRIESENBERG, Liechtenstein--(BUSINESS WIRE)--Lysando AG – market leader in the field of antimicrobial proteins – has signed a general development agreement with Amicogen Inc., a publicly traded biotechnology company and CDMO headquartered in South Korea.



In August last year, Lysando and Amicogen entered into a strategic partnership backed up by a mutual participation model. This collaboration has since been further intensified, now culminating in aforementioned general development agreement.
